No Data Yet
The U.S. healthcare sector advanced, buoyed by a significant biotech rally that overshadowed negative news from major pharmaceutical firms. The NYSE Health Care Index rose 0.9% amid a broader market rotation away from technology stocks.
First Horizon Corporation will announce its fourth-quarter and full-year 2025 financial results on January 15, 2026. The announcement, followed by a management conference call, comes at a time of significant market uncertainty and mixed performance across major industries.
The Federal Reserve's third interest rate cut of the year has spurred a rally in consumer discretionary stocks. Analysts are upgrading key players like Las Vegas Sands, citing strong performance metrics and a favorable economic outlook fueled by expectations of increased consumer spending.
Halliburton scheduled its Q4 2025 earnings call for January 21, 2026. This announcement aligns with the broader market trend of major corporations releasing financial guidance for the upcoming year, setting investor expectations across sectors.
Immunome, Inc. announced positive topline data from the Phase 3 RINGSIDE trial for its desmoid tumor therapy, varegacestat, leading to a significant rally in its stock. The drug demonstrated a substantial improvement in progression-free survival and tumor response compared to a placebo.
